Literature DB >> 23429387

Metabolic characteristics of Castleman disease on 18F-FDG PET in relation to clinical implication.

Eun Seong Lee1, Jin Chul Paeng, Chang Min Park, Won Chang, Won Woo Lee, Keon Wook Kang, June-Key Chung, Dong Soo Lee.   

Abstract

PURPOSE: Castleman disease (CD) is a benign lymphoproliferative disease, which usually shows hypermetabolism on 18F-FDG PET/CT. In this study, we investigated metabolic characteristics of CD in consecutive series of patients and analyzed 18F-FDG uptake with regard to major clinicopathologic factors, to investigate clinical implication of 18F-FDG uptake in CD.
METHODS: Twelve patients (5 men and 7 women; mean age, 52 ± 14 years) with pathologically confirmed CD, who underwent 18F-FDG PET/CT, were retrospectively enrolled, and their images were analyzed. The cases were composed of 10 first diagnosed and 2 relapsed cases. SUV(max) was measured for each lesion. Metabolic characteristics were compared according to clinical and pathologic characteristics.
RESULTS: All the 18F-FDG PET/CT images showed hypermetabolic lesions including small lymph nodes of less than 1 cm. The average SUV(max) was 5.8 ± 4.1 with a varying range of 2.4 to 17.1. SUVmax was significantly higher in multicentric than in unicentric disease cases (7.0 ± 4.6 vs 3.3 ± 1.1; P = 0.048) and in the patients with clinical manifestation than the other group (7.1 ± 4.5 and 3.1 ± 0.8, respectively; P = 0.028).
CONCLUSIONS: 18F-FDG PET/CT is an effective diagnostic imaging for diagnosis of CD. Castleman disease shows moderately increased 18F-FDG uptake. In addition, the uptake is well correlated with disease multicentricity and clinical manifestation, suggesting that it would be a significant imaging marker for severity or prognosis of CD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23429387     DOI: 10.1097/RLU.0b013e3182816730

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  17 in total

1.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  Blood       Date:  2017-01-13       Impact factor: 22.113

2.  (18)F-FDG PET/CT in multicentric Castleman disease: a case report.

Authors:  Qiyong Ding; Jiexin Zhang; Lu Yang
Journal:  Ann Transl Med       Date:  2016-02

3.  18F-fluorodeoxyglucose Positron Emission Tomography in Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease: Correlation With Activity, Severity, Inflammatory and Virologic Parameters.

Authors:  Mark N Polizzotto; Corina Millo; Thomas S Uldrick; Karen Aleman; Millie Whatley; Kathleen M Wyvill; Deirdre O'Mahony; Vickie Marshall; Denise Whitby; Roberto Maass-Moreno; Seth M Steinberg; Richard F Little; Robert Yarchoan
Journal:  J Infect Dis       Date:  2015-03-31       Impact factor: 5.226

4.  The role of FDG PET/CT in evaluation of mediastinal masses and neurogenic tumors of chest wall.

Authors:  Ebru Tatci; Ozlem Ozmen; Yeliz Dadali; Inci Uslu Biner; Atila Gokcek; Funda Demirag; Funda Incekara; Nuri Arslan
Journal:  Int J Clin Exp Med       Date:  2015-07-15

5.  Lymphadenopathy in POEMS syndrome: a correlation between clinical features and imaging findings.

Authors:  Xiao-Feng Shi; Shu-Dong Hu; Li-Li Wu; Xiao-Yan Chen; Jian-Nong Wu; Xian-Qiu Yu; Dong-Ya Li; Min Chen; Yi-Chen Liu; Yan Zhu; Xiao-Dong Xi
Journal:  Int J Clin Exp Pathol       Date:  2020-01-01

6.  Multimodality imaging and clinical features in Castleman disease: single institute experience in 30 patients.

Authors:  A J Hill; S H Tirumani; M H Rosenthal; A B Shinagare; R D Carrasco; N C Munshi; N H Ramaiya; S A Howard
Journal:  Br J Radiol       Date:  2015-02-24       Impact factor: 3.039

7.  Laparoscopic treatment for retroperitoneal hyaline-vascular type localized Castleman's disease (LCD) in the iliac vessel region.

Authors:  Aiwen Le; Lili Shan; Zhonghai Wang; Xiaoyun Dai; Tianhui Xiao; Rong Zhuo; Rui Yuan
Journal:  Int J Clin Exp Med       Date:  2015-11-15

8.  18F-FDG PET/CT imaging features of patients with multicentric Castleman disease.

Authors:  Yuanyuan Jiang; Guozhu Hou; Zhaohui Zhu; Li Huo; Fang Li; Wuying Cheng
Journal:  Nucl Med Commun       Date:  2021-07-01       Impact factor: 1.690

Review 9.  Spectrum of [18F]FDG-PET/CT Findings in Benign Lymph Node Pathology.

Authors:  Merissa N Zeman; Clare Green; Esma A Akin
Journal:  Mol Imaging Biol       Date:  2021-01-29       Impact factor: 3.488

Review 10.  Emerging role of 18F-FDG PET/CT in Castleman disease: a review.

Authors:  Benjamin Koa; Austin J Borja; Mahmoud Aly; Sayuri Padmanabhan; Joseph Tran; Vincent Zhang; Chaitanya Rojulpote; Sheila K Pierson; Mark-Avery Tamakloe; Johnson S Khor; Thomas J Werner; David C Fajgenbaum; Abass Alavi; Mona-Elisabeth Revheim
Journal:  Insights Imaging       Date:  2021-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.